Brean Murray Carret & Company has initiated coverage on Pharmasset VRUS with a Buy rating and $174 price target.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Posted In: Price TargetInitiationAnalyst RatingsBiotechnologyBrean Murray Carret & CompanyHealth Carepharmasset
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
